ReviewImmune network2026
Dual Roles of MAIT Cells in the Tumor Microenvironment: Implications for Cancer Immunity and Therapy.
Review in Immune network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The MHC-I related protein 1 MR1 can bind host purine catabolites.The Journal of biological chemistry · 2026Article
- Dynamic Interplay Between Tumor Cells and the Immune System.Immune network · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal-associated invariant T (MAIT) cells are innate T cells that recognize riboflavin metabolites with canonical TCRs and develop in the thymus as memory cells. They account for 1%-10% of peripheral blood T cells in humans and are frequently observed within the tumor microenvironment (TME). However, their functional roles remain controversial. In certain tumors, infiltrated MAIT cells upregulate cytotoxic receptor NKG2D and effector cytokines, including IFNγ, TNFα, and granzyme, contributing to tumor control. In other settings, they exhibit reduced cytokine production, increased expression of inhibitory receptors such as PD-1, CTLA-4, and TIM-3, and are associated with unfavorable clinical outcomes. These discrepancies are influenced by the source of MR1 ligands, cytokine composition, and metabolic conditions within the TME. Meanwhile, due to the innate cytotoxicity and lack of alloreactivity, MAIT cells are attractive candidates for cellular immunotherapy. This review summarizes the functional dichotomy of MAIT cells in cancers and outlines strategies to harness their anti-tumor properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.